GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Marketable Securities

RemeGen Co (HKSE:09995) Marketable Securities : HK$0 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. RemeGen Co's Marketable Securities for the quarter that ended in Dec. 2024 was HK$0 Mil.


RemeGen Co Marketable Securities Historical Data

The historical data trend for RemeGen Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Marketable Securities Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Marketable Securities
Get a 7-Day Free Trial - - - - -

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 285.60 - 215.57 -

RemeGen Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


RemeGen Co  (HKSE:09995) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


RemeGen Co Marketable Securities Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
Executives
Wen Qingkai 2103 Interests held jointly with another person
Fang Jianmin 2103 Interests held jointly with another person
Lin Jian 2103 Interests held jointly with another person
Wang Weidong 2201 Interest of corporation controlled by you
Wang Liqiang 2103 Interests held jointly with another person
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Rongchang Holding Group Ltd. 2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership) 2103 Interests held jointly with another person
Yang Minhua 2103 Interests held jointly with another person
Xiong Xiaobin 2103 Interests held jointly with another person
Wei Jianliang 2103 Interests held jointly with another person
Wang Xudong 2103 Interests held jointly with another person
I-nova Limited 2101 Beneficial owner
Deng Yong 2103 Interests held jointly with another person
Morgan Stanley 2201 Interest of corporation controlled by you

RemeGen Co Headlines

No Headlines